This week, Tempus announced the acquisition of Paige, a leader in digital pathology. Paige brings nearly 7 million de-identified, clinically annotated slides from 45+ countries, plus the first FDA-cleared AI pathology application, strengthening Tempus’s mission to build the largest oncology foundation model ever.
Key takeaways:
- Beyond the dataset: While the dataset is historic in scale, the value also comes from the pathologists, scientists, engineers, and QA specialists whose expertise built Paige’s tools.
- Infrastructure is essential: Data without pipelines and adoption pathways is like “oil in the ground”, powerful, but untapped without the right pipelines.
- Market dynamics: Investors reward scale of data more than brilliance of models, though long-term impact will hinge on usability and adoption.
- Execution matters: Interoperability and readiness affect adoption, but so does operational execution. Delivering value hinges on the right strategy.
- This deal is not just about dataset growth, it’s a moment for the health AI field to reflect on what truly drives progress: scale, yes, but also infrastructure, adoption, and human expertise.
